THE NEW HEALTH SPAN

Andrea Maier
Professor and researcher at the Centre for Healthy Longevity, Singapore, specializing in social relationships, wellbeing, and ageing across the life course.

Hassan Al Mulla
Senior advisor to the Minister of Public Health. Previously held leadership roles at Silatech, Royal Dutch Shell and Ooredoo.

Report Scope
This report examines the convergence of ageing populations, advances in senescence research, and the economic implications of extended health span at a critical inflection point in 2026.

It assesses how recent developments in cellular reprogramming and epigenetic interventions are moving from laboratory research to clinical application and will analyze the lack of integrated frameworks linking biogerontology research to policy and community-level implementation, highlighting the gap between longevity science and societal readiness.

Francesca Colombo
Oversees work on health at OECD and has over 25 years of experience leading international activities on health and health systems.

Panos Kanavos
Economist at the London School of Economics and Political Science, with expertise in pharmaceutical and medical technology policy, pricing, health technology assessment, and digital health.

Report Scope
This report examines the emergence of gene therapies, CAR-T cells, and one-time curative treatments as they reach market maturity in 2026 and assesses the sustainability challenges posed by current cost-per-cure models.

It also analyzes the inadequacy of existing financing frameworks for high-cost, one-time cures and will explore the widening gap between medical innovation and access, including the limited use of outcome-based and subscription models at scale.

Lord Darzi
Executive Chair of WISH and Head of the Global Health Institute at Imperial College London

Ahmed K. Elmagarmid
Founded the Qatar Computing Research Institute (QCRI) in 2010 and has served as its Executive Director since.

Report Scope
This report examines the large-scale viability of AI-powered primary care platforms following the accelerated digital health adoption after COVID-19.

It also assesses the clinical maturity of generative, large language, and multimodal AI systems in 2026, and analyzes how health systems can ensure AI augments human expertise and maintains equity, given the current lack of frameworks for responsible AI deployment, particularly in low-resource settings.

Françoise Shenfield
Honorary Associate Professor in Reproductive Health at UCL and clinician at UCLH London, specializing in fertility medicine and the ethics of assisted reproduction.

Johhny Awwad
Executive Chair, Women’s Services Division Chief, Reproductive Medicine, Sidra Medicine, Qatar. He has 25 years of experience as a Fertility Consultant.

Report Scope
This report examines rapid advances in reproductive technologies, including egg freezing, gene editing, and AI-driven embryo selection, and the ethical and policy challenges emerging in 2026.

It also assesses the growth of the global fertility market alongside equity and access concerns. It will also analyze fragmented and inconsistent global governance, highlighting the widening gap between technological innovation and ethical and policy frameworks.